PD-L1 siRNA

PD-L1 siRNA refers to small interfering RNA molecules specifically designed to silence the expression of programmed death-ligand 1 (PD-L1) gene (CD274), a crucial immune checkpoint protein frequently upregulated in cancer cells and immune cells within the tumor microenvironment. By binding directly to PD-L1 mRNA, these siRNA molecules prompt its degradation, thereby reducing both the mRNA and protein levels of PD-L1 in targeted cells. This gene-silencing approach enhances anti-tumor immune responses by diminishing PD-L1-mediated inhibition of T cell activity. Recent advances have focused on the use of biodegradable nanoparticles, liposomes, and other nanocarrier systems to deliver PD-L1 siRNA to tumor tissue, improving stability, cellular uptake, and therapeutic effect. Preclinical studies demonstrate that delivery of PD-L1 siRNA can sensitize tumor cells to T cell cytotoxicity, reduce tumor growth, and overcome chemotherapy resistance. PD-L1 siRNAs are being investigated primarily as potential immunotherapies and in combination with chemotherapeutics or other immunomodulating agents for various cancers[1][2][4][5][6][7][10].

Other names

programmed death-ligand 1 siRNACD274 siRNACD-274 siRNACD 274 siRNAB7-H1 siRNAB-7-H1 siRNAB 7-H1 siRNA